Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure.

Anti-cancer drug design Pub Date : 2000-04-01
O Keskin, I Bahar, R L Jernigan, J A Beutler, R H Shoemaker, E A Sausville, D G Covell
{"title":"Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure.","authors":"O Keskin,&nbsp;I Bahar,&nbsp;R L Jernigan,&nbsp;J A Beutler,&nbsp;R H Shoemaker,&nbsp;E A Sausville,&nbsp;D G Covell","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>An analysis of the growth inhibitory potency of 122 anticancer agents available from the National Cancer Institute anticancer drug screen is presented. Methods of singular value decomposition (SVD) were applied to determine the matrix of distances between all compounds. These SVD-derived dissimilarity distances were used to cluster compounds that exhibit similar tumor growth inhibitory activity patterns against 60 human cancer cell lines. Cluster analysis divides the 122 standard agents into 25 statistically distinct groups. The first eight groups include structurally diverse compounds with reactive functionalities that act as DNA-damaging agents while the remaining 17 groups include compounds that inhibit nucleic acid biosynthesis and mitosis. Examination of the average activity patterns across the 60 tumor cell lines reveals unique 'fingerprints' associated with each group. A diverse set of structural features are observed for compounds within these groups, with frequent occurrences of strong within-group structural similarities. Clustering of cell types by their response to the 122 anticancer agents divides the 60 cell types into 21 groups. The strongest within-panel groupings were found for the renal, leukemia and ovarian cell panels. These results contribute to the basis for comparisons between log(GI(50)) screening patterns of the 122 anticancer agents and additional tested compounds.</p>","PeriodicalId":7927,"journal":{"name":"Anti-cancer drug design","volume":"15 2","pages":"79-98"},"PeriodicalIF":0.0000,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-cancer drug design","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

An analysis of the growth inhibitory potency of 122 anticancer agents available from the National Cancer Institute anticancer drug screen is presented. Methods of singular value decomposition (SVD) were applied to determine the matrix of distances between all compounds. These SVD-derived dissimilarity distances were used to cluster compounds that exhibit similar tumor growth inhibitory activity patterns against 60 human cancer cell lines. Cluster analysis divides the 122 standard agents into 25 statistically distinct groups. The first eight groups include structurally diverse compounds with reactive functionalities that act as DNA-damaging agents while the remaining 17 groups include compounds that inhibit nucleic acid biosynthesis and mitosis. Examination of the average activity patterns across the 60 tumor cell lines reveals unique 'fingerprints' associated with each group. A diverse set of structural features are observed for compounds within these groups, with frequent occurrences of strong within-group structural similarities. Clustering of cell types by their response to the 122 anticancer agents divides the 60 cell types into 21 groups. The strongest within-panel groupings were found for the renal, leukemia and ovarian cell panels. These results contribute to the basis for comparisons between log(GI(50)) screening patterns of the 122 anticancer agents and additional tested compounds.

抗癌药物生长抑制活性的表征及其作用机制和结构的关系。
从国家癌症研究所抗癌药物筛选提供的122种抗癌药物的生长抑制效力的分析。采用奇异值分解(SVD)方法确定所有化合物之间的距离矩阵。这些svd衍生的不相似距离被用来对60种人类癌细胞系表现出相似的肿瘤生长抑制活性模式的化合物进行聚类。聚类分析将122个标准代理分为25个具有统计学差异的组。前8组包括结构多样的具有反应性功能的化合物,作为dna损伤剂,其余17组包括抑制核酸生物合成和有丝分裂的化合物。对60种肿瘤细胞系的平均活动模式的检查揭示了与每一组相关的独特“指纹”。在这些基团中观察到化合物的不同结构特征,并且经常出现强烈的组内结构相似性。根据细胞对122种抗癌药物的反应将60种细胞类型分为21组。在肾、白血病和卵巢细胞组中发现了最强的组内分组。这些结果为比较122种抗癌药物和其他测试化合物的log(GI(50))筛选模式提供了基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信